NeuroSense Therapeutics (NASDAQ:NRSN) Trading 3.5% Higher – Time to Buy?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares shot up 3.5% during mid-day trading on Friday . The company traded as high as $1.13 and last traded at $1.11. 80,173 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 141,835 shares. The stock had previously closed at $1.07.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday, December 16th.

NeuroSense Therapeutics Trading Up 3.5 %

The business has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.11. The stock has a market capitalization of $15.14 million, a PE ratio of -1.73 and a beta of 1.27.

NeuroSense Therapeutics (NASDAQ:NRSN) last issued its earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several institutional investors have recently bought and sold shares of NRSN. Citadel Advisors LLC boosted its holdings in NeuroSense Therapeutics by 640.9% during the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock valued at $305,000 after acquiring an additional 219,717 shares during the period. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics during the 4th quarter valued at about $78,000. Finally, XTX Topco Ltd boosted its holdings in NeuroSense Therapeutics by 40.9% during the 3rd quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after acquiring an additional 13,346 shares during the period. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.